Connect with us

/home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153
">
Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

Warning: Attempt to read property "cat_name" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 153

MDA Awarded Canadian Government Contract to Deliver Search and Rescue Repeaters for Satellites

Published

on

Reading Time: 3 minutes

MONTREAL–(BUSINESS WIRE)–MDA, a Maxar company (NYSE: MAXR) (TSX: MAXR), has been awarded an
initial contract value of CAD $39 million with Public Services and
Procurement Canada. The initial contract includes the development and
manufacturing of 10 flight-ready Search and Rescue/Global Positioning
System (SAR/GPS) repeaters to be launched on the U.S. Air Force’s GPS
III satellites, as well as several automated test systems and simulators.

The contract includes options for an additional 12 flight model
repeaters which, if exercised by Canada, would increase the total
contract value in excess of $55 million. Once in orbit 22,000 kilometres
above the Earth, MDA’s MEOSAR repeater will be able to detect signals
from emergency beacons and retransmit the signals to receiver stations
on the ground. The emergency messages can then be sent to appropriate
authorities so that people in danger can be quickly located and rescued.

“This project builds on MDA’s previous successes and ensures MDA’s
commitment to develop innovative solutions that are vital to Canada’s
sovereignty and security,” said Mike Greenley, group president of MDA.
“Once qualified as operational, this system will dramatically improve
both the speed and location accuracy for detecting beacons, and as a
result greatly enhance the coordination and dispatch of search and
rescue teams to help people in distress.”

Satellites have become an integral part of Canada’s national
infrastructure, providing critical services on a daily basis to
individual Canadians and government agencies. With Canada’s vast
geography and long coastlines, satellites support a wide variety of
applications, from Search and Rescue, to ecosystem and climate change
monitoring, telecommunications, navigation and ice mapping, and
fisheries and natural resource management.

The operations of DigitalGlobe, SSL and Radiant Solutions were unified
under the Maxar brand in February; MDA continues to operate as an
independent business unit within the Maxar organization.

About MDA

MDA is an internationally recognized leader in space robotics, space
sensors, satellite payloads, antennas and subsystems, surveillance and
intelligence systems, defense and maritime systems, and geospatial radar
imagery. MDA’s extensive space expertise and heritage translates into
mission-critical defence and commercial applications that include
multi-platform command, control and surveillance systems, aeronautical
information systems, land administration systems and terrestrial
robotics. MDA is also a leading supplier of actionable mission-critical
information and insights derived from multiple data sources. Founded in
1969, MDA is recognized as one of Canada’s most successful technology
ventures with locations in Richmond, Ottawa, Brampton, Montreal, Halifax
and the United Kingdom. For more information, visit www.mdacorporation.com.

About Maxar Technologies

As a global leader of advanced space technology solutions, Maxar is at
the nexus of the new space economy, developing and sustaining the
infrastructure and delivering the information, services, and systems
that unlock the promise of space for commercial and government markets.
The operations of DigitalGlobe, SSL and Radiant Solutions were unified
under the Maxar brand in February; MDA continues to operate as an
independent business unit within the Maxar organization. As a trusted
partner with 5,900 employees in over 30 global locations, Maxar provides
vertically integrated capabilities and expertise including satellites,
Earth imagery, robotics, geospatial data and analytics to help customers
anticipate and address their most complex mission-critical challenges
with confidence. Every day, billions of people rely on Maxar to
communicate, share information and data, and deliver insights that Build
a Better World. Maxar trades on the New York Stock Exchange and Toronto
Stock Exchange as MAXR. For more information, visit www.maxar.com.

Forward-Looking Statements

Certain statements and other information included in this release
constitute “forward-looking information” or “forward-looking statements”
(collectively, “forward-looking statements”) under applicable securities
laws. Statements including words such as “may,” “will,” “could,”
“should,” “would,” “plan,” “potential,” “intend,” “anticipate,”
“believe,” “estimate” or “expect” and other words, terms and phrases of
similar meaning are often intended to identify forward-looking
statements, although not all forward-looking statements contain these
identifying words. Forward-looking statements involve estimates,
expectations, projections, goals, forecasts, assumptions, risks and
uncertainties, as well as other statements referring to or including
forward-looking information included in this presentation.

Forward-looking statements are subject to various risks and
uncertainties which could cause actual results to differ materially from
the anticipated results or expectations expressed in this presentation.
As a result, although management of the Company believes that the
expectations and assumptions on which such forward-looking statements
are based are reasonable, undue reliance should not be placed on the
forward-looking statements because the Company can give no assurance
that they will prove to be correct. The risks that could cause actual
results to differ materially from current expectations include, but are
not limited to, the risk factors and other disclosures about the Company
and its business included in the Company’s continuous disclosure
materials filed from time to time with U.S. securities and Canadian
regulatory authorities, which are available online under the Company’s
EDGAR profile at www.sec.gov,
under the Company’s SEDAR profile at www.sedar.com or
on the Company’s website at www.maxar.com.

The forward-looking statements contained in this release are expressly
qualified in their entirety by the foregoing cautionary statements. All
such forward-looking statements are based upon data available as of the
date of this presentation or other specified date and speak only as of
such date. The Company disclaims any intention or obligation to update
or revise any forward-looking statements in this presentation as a
result of new information or future events, except as may be required
under applicable securities legislation.

Contacts

Leslie Swartman
MDA Media Contact
1-613-736-6917
[email protected]

Jason
Gursky
Maxar Investor Relations
1-303-684-2207
[email protected]


Warning: Undefined array key 0 in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Warning: Attempt to read property "cat_ID" on null in /home/grassnews/public_html/wp-content/themes/zox-news/parts/post-single.php on line 493

Innocan

Innocan Pharma Announces Study Findings that LPT-CBD maintains its prolonged release in Rabbits

Published

on

innocan-pharma-announces-study-findings-that-lpt-cbd-maintains-its-prolonged-release-in-rabbits

HERZLIYA, Israel and CALGARY, AB, Feb. 26, 2024 /PRNewswire/ — Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (“Innocan” or the “Company”), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce the latest findings from the Company’s pharmacokinetic study of its LPT-CBD platform in rabbits.

The fundamentals of LPT-CBD lay in its ability to slowly release CBD into the blood stream. Studies conducted in various animal models including mice, dogs, goats, and sheep showed long pharmacokinetics of CBD that persisted up to several weeks. In the Company’s latest study conducted on rabbits, the results showed additional supportive data for the long exposure of CBD obtained following a single subcutaneous LPT-CBD injection.   

The Company is encouraged by these study results as they confirm the approach the Company is taking with its LPT platform. The results from studies of several organisms injected with the Company’s liposomal CBD –have consistently demonstrated that a detectable CBD level could be maintained for weeks following one injection. The Company will continue with human trials in the near future.

Pharmacokinetics (PK) is an important tool that helps evaluate the bioavailability and exposure level of a specific drug. Parameters such as maximal blood drug concentration (cMax), time to reach cMax (Tmax) and half-life of the drug are calculated based on data collected from blood analysis of the drug across a determined time. The collected PK parameters along with other tests help to define the required dose of a drug to achieve a maximal therapeutic effect. In the study conducted on rabbits, the animals were collected for blood analysis of the drug for up to 11 days. As expected, the animals presented a persistent CBD concentration in their blood that maintained through the entire testing period. This correlates to PK results obtained from other species, supporting the long CBD exposure and the necessity of only a single LPT-CBD injection to obtain a long and wide therapeutic window for CBD.   

About Innocan Pharma:

Innocan is a pharmaceutical tech company that operates under two main segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals segment, Innocan focuses on developing innovative drug delivery platform technologies comprises with cannabinoids science, to treat various conditions to improve patients’ quality of life. This segment involves two drug delivery technologies: (i) LPT CBD-loaded liposome platform facilitating exact dosing and the prolonged and controlled release of CBD into the blood stream. The LPT delivery platform research is in the preclinical trial phase for two indications: Epilepsy and Pain Management. In the Consumer Wellness segment, Innocan develops and markets a wide portfolio of innovative and high-performance self-care products to promote a healthier lifestyle. Under this segment Innocan has established a Joint Venture by the name of BI Sky Global Ltd. that focuses developing on advanced targeted online sales. https://innocanpharma.com/

Contact Information:

For Innocan Pharma Corporation:
Iris Bincovich, CEO
+1 5162104025
+972-54-3012842
+442037699377
info@innocanpharma.com

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Caution Regarding Forward-Looking Information

Certain information set forth in this news release, including, without limitation, the Company’s plans for human trials of its LPT-CBD platform, is forward-looking information within the meaning of applicable securities laws. By its nature, forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan’s control. . The forward-looking information contained in this news release is based on certain key expectations and assumptions made by Innocan, including expectations and assumptions concerning the anticipated benefits of the products, satisfaction of regulatory requirements in various jurisdictions and satisfactory completion of production and distribution arrangements.

Forward-looking information is subject to various risks and uncertainties that could cause actual results and experience to differ materially from the anticipated results or expectations expressed in this news release. The key risks and uncertainties include but are not limited to: global and local (national) economic, political, market and business conditions; governmental and regulatory requirements and actions by governmental authorities; and potential disruption of relationships with suppliers, manufacturers, customers, business partners and competitors. There are also risks that are inherent in the nature of product distribution, including import/export matters and the failure to obtain any required regulatory and other approvals (or to do so in a timely manner). The anticipated timeline for entry to markets may change for a number of reasons, including the inability to secure necessary regulatory requirements, or the need for additional time to conclude and/or satisfy the manufacturing and distribution arrangements. As a result of the foregoing, readers should not place undue reliance on the forward-looking information contained in this news release. A comprehensive discussion of other risks that impact Innocan can be found in Innocan’s public reports and filings which are available under Innocan’s profile at www.sedarplus.ca.

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law.

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/innocan-pharma-announces-study-findings-that-lpt-cbd-maintains-its-prolonged-release-in-rabbits-302069807.html

Continue Reading

SCHWAZZE

Schwazze Appoints Forrest Hoffmaster as Interim Chief Executive Officer

Published

on

schwazze-appoints-forrest-hoffmaster-as-interim-chief-executive-officer

DENVER, Feb. 23, 2024 /PRNewswire/ — Medicine Man Technologies, Inc., operating as Schwazze, (OTCQX: SHWZ) (NEO: SHWZ) (“Schwazze” or the “Company”), today announced that Forrest Hoffmaster, the Company’s Chief Financial Officer, has been appointed to the additional role of interim Chief Executive Officer (“CEO”). This follows Nirup Krishnamurthy’s resignation as CEO and as a member of the Board of Directors (“Board”), effective February 20, 2024, due to personal reasons.

Mr. Hoffmaster, who joined the Company in January 2023, brings over 30 years of executive experience in finance and operations for both public and private companies. Prior to Schwazze, Mr. Hoffmaster served as CEO of New Seasons Market, a specialty gourmet food retailer, where he navigated the company through one of the most disruptive periods in the retail grocery industry. Under his leadership, Mr. Hoffmaster implemented a focused growth and cost optimization program, enabling the company to grow EBITDA by over 30% in two years. Prior to New Seasons Market, Forrest held leadership positions with other leading grocers including Whole Foods Market and H-E-B.

“Forrest is well-positioned to seamlessly step in and lead the Company’s day-to-day operations as we conduct our search for a permanent successor,” said Justin Dye, Chairman of the Board. “With Forrest’s proven track record and deep retail expertise, we plan to continue leveraging our operating playbook to drive strong Adjusted EBITDA margins and consistent cash flow generation. On behalf of the Board, I’d like to wish Nirup the best in his future endeavors.”

About Schwazze

Schwazze (OTCQX: SHWZ) (NEO: SHWZ) is building a premier vertically integrated regional cannabis company with assets in Colorado and New Mexico and will continue to take its operating system to other states where it can develop a differentiated regional leadership position. Schwazze is the parent company of a portfolio of leading cannabis businesses and brands spanning seed to sale.

Schwazze is anchored by a high-performance culture that combines customer-centric thinking and data science to test, measure, and drive decisions and outcomes. The Company’s leadership team has deep expertise in retailing, wholesaling, and building consumer brands at Fortune 500 companies as well as in the cannabis sector.

Medicine Man Technologies, Inc. was Schwazze’s former operating trade name. The corporate entity continues to be named Medicine Man Technologies, Inc. Schwazze derives its name from the pruning technique of a cannabis plant to enhance plant structure and promote healthy growth. To learn more about Schwazze, visit https://schwazze.com/.

Forward-Looking Statements

This press release contains “forward-looking statements.” Such statements may be preceded by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intends,” “plans,” “strategy,” “prospects,” “anticipate,” “believe,” “approximately,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” or the negative of these terms or other words of similar meaning in connection with a discussion of future events or future operating or financial performance, although the absence of these words does not necessarily mean that a statement is not forward-looking. Forward-looking statements are not guarantees of future events or performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified. Consequently, actual events and results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) regulatory limitations on our products and services and the uncertainty in the application of federal, state, and local laws to our business, and any changes in such laws; (ii) our ability to manufacture our products and product candidates on a commercial scale on our own or in collaboration with third parties; (iii) our ability to identify, consummate, and integrate anticipated acquisitions; (iv) general industry and economic conditions; (v) our ability to access adequate capital upon terms and conditions that are acceptable to us; (vi) our ability to pay interest and principal on outstanding debt when due; (vii) volatility in credit and market conditions; (viii) the loss of one or more key executives or other key employees; and (ix) other risks and uncertainties related to the cannabis market and our business strategy. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise except as required by law.

Investor Relations Contact
Sean Mansouri, CFA or Aaron D’Souza
Elevate IR
(720) 330-2829
[email protected] 

View original content:https://www.prnewswire.co.uk/news-releases/schwazze-appoints-forrest-hoffmaster-as-interim-chief-executive-officer-302069402.html

Continue Reading

Cannabis

Hemp, Inc. Reports: Hemp-Based Foods Market Set to Reach $8.36 Billion by 2028

Published

on

Continue Reading

Trending on Grassnews

GrassNews.net: Your premier portal for the latest developments in the cannabis industry. We provide timely news, insightful analysis, and in-depth features on everything from legislation changes and business trends, to scientific research and lifestyle topics. Stay informed and navigate the rapidly evolving cannabis landscape with GrassNews.net..

Contact us: [email protected]

Editorial / PR Submissions

Copyright © 2007 - 2024 Hipther Agency. Registered in Romania under Proshirt SRL, Company number: 2134306, EU VAT ID: RO21343605. Office address: Blvd. 1 Decembrie 1918 nr.5, Targu Mures, Romania